We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ovid Therapeutics Inc | NASDAQ:OVID | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0301 | 0.96% | 3.1801 | 3.17 | 3.18 | 3.20 | 3.10 | 3.15 | 26,352 | 18:56:36 |
*
|
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
|
|
|
|
|
|
|
|
||||||
(1)
|
|
Names of reporting persons
Takeda Pharmaceutical Company Limited
|
||||||||||
(2)
|
|
Check the appropriate box if a member of a group (see instructions)
(a) ☐ (b) ☐
|
||||||||||
(3)
|
|
SEC use only
|
||||||||||
(4)
|
|
Citizenship or place of organization
Japan
|
||||||||||
Number of
shares
beneficially
owned by
each
reporting
person
with:
|
|
(5)
|
|
Sole voting power
1,781,996
|
||||||||
|
(6)
|
|
Shared voting power
5,750,000
|
|||||||||
|
(7)
|
|
Sole dispositive power
1,781,996
|
|||||||||
|
(8)
|
|
Shared dispositive power
5,750,000
|
|||||||||
(9)
|
|
Aggregate amount beneficially owned by each reporting person
7,531,996 (1)
|
||||||||||
(10)
|
|
Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
☐
|
||||||||||
(11)
|
|
Percent of class represented by amount in Row (9)
15.8% (2)
|
||||||||||
(12)
|
|
Type of reporting person (see instructions)
CO
|
|
|
|
|
|
|
|
||||||
(1)
|
|
Names of reporting persons
Millennium Pharmaceuticals, Inc.
|
||||||||||
(2)
|
|
Check the appropriate box if a member of a group (see instructions)
(a) ☐ (b) ☐
|
||||||||||
(3)
|
|
SEC use only
|
||||||||||
(4)
|
|
Citizenship or place of organization
United States
|
||||||||||
Number of
shares
beneficially
owned by
each
reporting
person
with:
|
|
(5)
|
|
Sole voting power
0
|
||||||||
|
(6)
|
|
Shared voting power
5,750,000
|
|||||||||
|
(7)
|
|
Sole dispositive power
0
|
|||||||||
|
(8)
|
|
Shared dispositive power
5,750,000
|
|||||||||
(9)
|
|
Aggregate amount beneficially owned by each reporting person
5,750,000
|
||||||||||
(10)
|
|
Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
☐
|
||||||||||
(11)
|
|
Percent of class represented by amount in Row (9)
12% (1)
|
||||||||||
(12)
|
|
Type of reporting person (see instructions)
CO
|
Item 1(a)
|
Name of issuer:
|
Item 1(b)
|
Address of issuer’s principal executive offices:
|
Item 2(a)
|
Name of person filing:
|
Item 2(b)
|
Address of principal business office or, if none, residence:
|
Item 2(c)
|
Citizenship:
|
Item 2(d)
|
Title of class of securities:
|
Item 2(e)
|
CUSIP No.:
|
Item 3.
|
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
|
Item 4.
|
Ownership
|
Item 5.
|
Ownership of 5 Percent or Less of a Class.
|
Item 6.
|
Ownership of More than 5 Percent on Behalf of Another Person.
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
|
Item 8.
|
Identification and Classification of Members of the Group.
|
Item 9.
|
Notice of Dissolution of Group.
|
Item 10.
|
Certifications
|
TAKEDA PHARMACEUTICAL COMPANY LIMITED
|
||
|
||
By
|
/s/ Yoshihiro Nakagawa
|
|
|
Name:
|
Yoshihiro Nakagawa
|
|
Title:
|
Corporate Officer, Global General Counsel
|
MILLENNIUM PHARMACEUTICALS, INC.
|
||
|
||
By
|
/s/ Paul Sundberg
|
|
|
Name:
|
Paul Sundberg
|
|
Title:
|
Attorney-in-Fact
|
Exhibit 99.1
|
Exhibit 99.2
|
1 Year Ovid Therapeutics Chart |
1 Month Ovid Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions